Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Humanetics receives licenses for medical radiation countermeasures

Aug. 16, 2010

Nabilone shows promise to treat cannabis use disorders

Aug. 10, 2010

Patient enrollment advances ahead of schedule in phase III Probuphine trial

Aug. 4, 2010

FDA grants CBLB-502 fast track status for acute radiation syndrome

July 23, 2010

Cangene's option to license Maxygen's MAXY-G34 for ARS expires

July 19, 2010

Nabi completes enrollment in first of two phase III NicVAX trials

July 15, 2010

Effect of citalopram on drinking depends on goals of alcohol-dependent subjects

July 13, 2010

FDA schedules review of Alkermes' Vivitrol sNDA for opioid dependence

June 21, 2010

Protalix BioTherapeutics completes phase I trial of PRX-105

June 10, 2010

FDA grants priority review to Vivitrol sNDA for opioid dependence

May 27, 2010

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...